| Literature DB >> 24239173 |
Masanobu Tsubaki1, Makiko Komai1, Tatsuki Itoh2, Motohiro Imano3, Kotaro Sakamoto1, Hirotaka Shimaoka1, Tomoya Takeda1, Naoki Ogawa4, Kenji Mashimo5, Daiichiro Fujiwara5, Junji Mukai6, Katsuhiko Sakaguchi7, Takao Satou2, Shozo Nishida8.
Abstract
The calcium channel blocker verapamil inhibits the transport function of multidrug resistance protein 1 (MDR1). Although verapamil acts to reverse MDR in cancer cells, the underlying mechanism remains unclear. In the present study, we investigated the mechanism of reversing MDR by verapamil in anti-cancer drug-resistant multiple myeloma (MM) cell lines. We found that verapamil suppresses MDR1 and survivin expressions and increases Bim expression via suppression of Src activation. Furthermore, dasatinib reversed the drug-resistance of the drug-resistant cell lines. These findings suggest that Src inhibitors are potentially useful as an anti-MDR agent for the treatment of malignant tumor cells.Entities:
Keywords: ATP; Bim; Dasatinib; Drug resistance; MDR; MDR1; MM; Multiple myeloma; PBS; Src; Survivin; Verapamil; adenosine triphosphate; multi-drug resistance; multidrug resistance protein 1; multiple myeloma; phosphate buffer saline.
Mesh：
Substances：
Year: 2013 PMID： 24239173 DOI： 10.1016/j.leukres.2013.10.017
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156